Valuation: Silence Therapeutics plc

Market Cap 383M 515M 450M 415M 722M 49.55B 737M 4.96B 1.95B 24.28B 1.93B 1.89B 83.59B P/E 2026 *
-18.3x
P/E 2027 * -16.3x
Enterprise Value 236M 318M 278M 256M 445M 30.59B 455M 3.06B 1.2B 14.98B 1.19B 1.17B 51.6B EV / Sales 2026 *
94.6x
EV / Sales 2027 * 38.7x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
1 week+6.49%
Current month-4.37%
1 month+56.48%
3 months+38.16%
6 months+108.33%
Current year+72.70%
1 week 8.91
Extreme 8.91
11.19
1 month 6.52
Extreme 6.52
11.19
Current year 4.19
Extreme 4.19
11.19
1 year 4.19
Extreme 4.19
11.19
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 01/12/2025
Director of Finance/CFO 54 01/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/01/2004
Director/Board Member 65 05/05/2025
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell 865,112 0.6105%
02/01/26 Free

Chief Technology Officer

300,000 0.2117%
02/01/26 Free

Chief Financial Officer

375,000 0.2646%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%+6.49%+65.35%+81.03% 516M
-1.29%-2.54%-0.35%+4.30% 49.7B
+3.90%-2.60%+384.79%+598.27% 38.09B
-1.70%+3.03%+11.77%+58.93% 35.29B
-2.01%-1.30%+30.02%-6.71% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
+0.46%-5.24% - - 16.14B
-0.04%+0.42%+70.80%+121.10% 15.36B
+1.12%+2.15%+16.24%+19.12% 13.89B
0.00%+0.73%+18.02%-30.96% 13.02B
Average -0.34%+0.57%+66.78%+96.94% 24.44B
Weighted average by Cap. -0.10%-0.62%+78.05%+119.87%

Financials

2026 *2027 *
Net sales 2.5M 3.36M 2.94M 2.71M 4.71M 323M 4.81M 32.4M 12.72M 158M 12.6M 12.34M 546M 3.44M 4.63M 4.05M 3.74M 6.49M 446M 6.63M 44.67M 17.53M 218M 17.38M 17.01M 752M
Net income -50.43M -67.84M -59.29M -54.75M -95.12M -6.53B -97.17M -654M -257M -3.2B -255M -249M -11.02B -84.79M -114M -99.68M -92.06M -160M -10.98B -163M -1.1B -432M -5.38B -428M -419M -18.53B
Net Debt -146M -197M -172M -159M -276M -18.97B -282M -1.9B -746M -9.29B -739M -724M -31.99B -249M -336M -293M -271M -470M -32.3B -481M -3.24B -1.27B -15.83B -1.26B -1.23B -54.49B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
17/07/26 $10.50 -3.85% 277,229
16/07/26 $10.92 +4.50% 567,829
15/07/26 $10.45 +7.18% 791,970
14/07/26 $9.750 +4.95% 338,977
13/07/26 $9.290 +2.20% 233,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.92USD
Average target price
29.17USD
Spread / Average Target
+167.09%

Quarterly revenue - Rate of surprise